DK3110420T3 - Salte af heterocykliske modulatorer af hif-aktivitet til behandling af sygdomme - Google Patents
Salte af heterocykliske modulatorer af hif-aktivitet til behandling af sygdomme Download PDFInfo
- Publication number
- DK3110420T3 DK3110420T3 DK15755054.2T DK15755054T DK3110420T3 DK 3110420 T3 DK3110420 T3 DK 3110420T3 DK 15755054 T DK15755054 T DK 15755054T DK 3110420 T3 DK3110420 T3 DK 3110420T3
- Authority
- DK
- Denmark
- Prior art keywords
- diseases
- salt
- treatment
- hif activity
- heterocyclic modulators
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461944345P | 2014-02-25 | 2014-02-25 | |
| PCT/US2015/017533 WO2015130790A2 (en) | 2014-02-25 | 2015-02-25 | Salts of heterocyclic modulators of hif activity for treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3110420T3 true DK3110420T3 (da) | 2019-05-13 |
Family
ID=53881577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15755054.2T DK3110420T3 (da) | 2014-02-25 | 2015-02-25 | Salte af heterocykliske modulatorer af hif-aktivitet til behandling af sygdomme |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US9663504B2 (da) |
| EP (1) | EP3110420B8 (da) |
| DK (1) | DK3110420T3 (da) |
| ES (1) | ES2726648T3 (da) |
| WO (1) | WO2015130790A2 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9018380B2 (en) | 2012-08-24 | 2015-04-28 | Boar of Regents, The University of Texas System | Heterocyclic modulators of HIF activity for treatment of disease |
| KR102280614B1 (ko) | 2013-03-15 | 2021-07-21 | 글로벌 블러드 테라퓨틱스, 인크. | 헤모글로빈 조정을 위한 화합물 및 이의 용도 |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| US9663504B2 (en) | 2014-02-25 | 2017-05-30 | Board Of Regents, The University Of Texas System | Salts of heterocyclic modulators of HIF activity for treatment of disease |
| SG11202001684PA (en) | 2017-10-06 | 2020-03-30 | Forma Therapeutics Inc | Inhibiting ubiquitin specific peptidase 30 |
| ES2988920T3 (es) | 2018-05-17 | 2024-11-22 | Forma Therapeutics Inc | Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina |
| PL3860989T3 (pl) | 2018-10-05 | 2023-07-10 | Forma Therapeutics, Inc. | Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30) |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| IL326597A (en) | 2019-10-07 | 2026-04-01 | Contineum Therapeutics Inc | Muscarinic M1 acetylcholine receptor antagonists |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1480030A (en) | 1924-01-08 | Razor and stropping device | ||
| US1528517A (en) | 1923-08-09 | 1925-03-03 | Mearl V Tracy | Table |
| TW401408B (en) | 1995-07-21 | 2000-08-11 | Fujisawa Pharmaceutical Co | Heterocyclic compounds having prostaglandin I2 agonism |
| AUPP608898A0 (en) | 1998-09-23 | 1998-10-15 | Fujisawa Pharmaceutical Co., Ltd. | New use of prostaglandin E2 antagonists |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| ES2334990T3 (es) | 2002-02-14 | 2010-03-18 | Pharmacia Corporation | Piridinonas sustituidas como moduladores de p38 map quinasa. |
| GB0315657D0 (en) * | 2003-07-03 | 2003-08-13 | Astex Technology Ltd | Pharmaceutical compounds |
| NL1026826C2 (nl) | 2003-08-13 | 2007-01-04 | Pharmacia Corp | Gesubstitueerde pyridinonen. |
| WO2005116736A1 (en) | 2004-05-28 | 2005-12-08 | Koninklijke Philips Electronics N.V. | Method of forming a film for a colour filter of a transflective liquid crystal display |
| WO2006070198A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| WO2006116736A2 (en) | 2005-04-27 | 2006-11-02 | Siemens Medical Solutions Usa, Inc. | A method for the preparation of imaging probes using click chemistry |
| KR20080068839A (ko) | 2005-10-03 | 2008-07-24 | 오노 야꾸힝 고교 가부시키가이샤 | 질소 함유 복소환 화합물 및 그 의약 용도 |
| EP2038272B8 (en) | 2006-06-30 | 2013-10-23 | Sunesis Pharmaceuticals, Inc. | Pyridinonyl pdk1 inhibitors |
| EP2148877A2 (en) * | 2007-05-18 | 2010-02-03 | Bayer Schering Pharma AG | Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| DE102007025718A1 (de) | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | Pyridazinonderivate |
| CA2691662A1 (en) | 2007-07-02 | 2009-01-08 | F. Hoffmann-La Roche Ag | Imidazole derivatives as ccr2 receptor antagonists |
| US20110229469A1 (en) | 2008-10-01 | 2011-09-22 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
| AU2009315930A1 (en) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Heteroaromatic compounds for use as HIF inhibitors |
| DE102008057344A1 (de) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung |
| HRP20150341T1 (hr) * | 2008-11-14 | 2015-05-08 | Bayer Intellectual Property Gmbh | Heterocikliäśki supstituirani spojevi arila kao inhibitori hif |
| BR112012000915A2 (pt) | 2009-07-15 | 2019-09-24 | Janssen Pharmaceuticals Inc | derivados de triazol e imidazol substituídos como moduladores de gama secretase. |
| MX2012012905A (es) | 2010-05-08 | 2012-12-17 | Bayer Ip Gmbh | Hidroxialquilbencilpirazoles y su uso para tratamiento de enfermedades hiperproliferativas y angiogenicas. |
| BR112012028651A2 (pt) | 2010-05-08 | 2016-08-09 | Bayer Ip Gmbh | heterociclilbenzilpirazóis substituídos e uso do mesmo |
| WO2013057101A1 (de) | 2011-10-17 | 2013-04-25 | Bayer Intellectual Property Gmbh | Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer |
| WO2014031933A2 (en) | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
| US9018380B2 (en) | 2012-08-24 | 2015-04-28 | Boar of Regents, The University of Texas System | Heterocyclic modulators of HIF activity for treatment of disease |
| US20140073634A1 (en) | 2012-08-24 | 2014-03-13 | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center | Heterocyclic modulators of hif activity for treatment of disease |
| US9663504B2 (en) | 2014-02-25 | 2017-05-30 | Board Of Regents, The University Of Texas System | Salts of heterocyclic modulators of HIF activity for treatment of disease |
-
2015
- 2015-02-25 US US14/631,454 patent/US9663504B2/en not_active Expired - Fee Related
- 2015-02-25 WO PCT/US2015/017533 patent/WO2015130790A2/en not_active Ceased
- 2015-02-25 DK DK15755054.2T patent/DK3110420T3/da active
- 2015-02-25 ES ES15755054T patent/ES2726648T3/es active Active
- 2015-02-25 EP EP15755054.2A patent/EP3110420B8/en not_active Not-in-force
-
2017
- 2017-04-20 US US15/492,751 patent/US10363248B2/en not_active Expired - Fee Related
-
2019
- 2019-06-24 US US16/450,060 patent/US10888554B2/en not_active Expired - Fee Related
-
2020
- 2020-12-08 US US17/115,216 patent/US20210137910A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3110420B8 (en) | 2019-07-10 |
| WO2015130790A2 (en) | 2015-09-03 |
| US9663504B2 (en) | 2017-05-30 |
| EP3110420B1 (en) | 2019-02-13 |
| EP3110420A2 (en) | 2017-01-04 |
| US20210137910A1 (en) | 2021-05-13 |
| WO2015130790A3 (en) | 2016-01-28 |
| US20150239876A1 (en) | 2015-08-27 |
| US20170216271A1 (en) | 2017-08-03 |
| US10888554B2 (en) | 2021-01-12 |
| EP3110420A4 (en) | 2017-07-05 |
| US20200171017A1 (en) | 2020-06-04 |
| US10363248B2 (en) | 2019-07-30 |
| ES2726648T3 (es) | 2019-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR24C1022I2 (fr) | Modulation d'activité du complément | |
| IL285114A (en) | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3171928T3 (da) | Stimulationsmønstre til behandling af tørt øje | |
| DK3450553T3 (da) | Mrna-terapi til behandling af øjensygdomme | |
| DK3204113T3 (da) | Apparat til stimulering af biologisk væv | |
| DK3166976T3 (da) | Anti-pd-l1-kombinationer til behandling af tumorer | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3169328T3 (da) | Quinolinderivater til behandling af inflammationssygdomme | |
| IL253394B (en) | Heterocyclic compounds for cancer imaging and treatment and methods for their use | |
| EP3110420B8 (en) | Salts of heterocyclic modulators of hif activity for treatment of disease | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| HUE059303T2 (hu) | Acetilkolin-észteráz-gátlók bõrbetegségek kezelésére | |
| LT3685847T (lt) | Komplemento aktyvumo moduliatoriai | |
| DK3097085T3 (da) | Benzoxazinonderivater til behandling af hudsygdomme | |
| DK3164394T3 (da) | Gls1-inhibitorer til behandling af sygdomme | |
| DK3210973T3 (da) | Heteroarylforbindelser til behandling af oftalmiske sygdomme | |
| HUE056613T2 (hu) | Komplementaktivitás modulátorai | |
| HUE048924T2 (hu) | Csont morfogenetikus fehérjék terápiás alkalmazása | |
| IL256103B (en) | Compositions and methods for treating celiac sprue disease | |
| IL257355B (en) | Selection of patients for combination therapy | |
| LT3119384T (lt) | Intrahepatinių cholestazinių ligų gydymas | |
| IL257764B (en) | Methods for treatment of diseases | |
| EP3337474A4 (en) | QUANTITATIVE PERIORBITAL APPLICATION OF EYE DISORDER |